^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    matuzumab (EMD 72000)

    i
    Other names: EMD 72000
    Associations

    News

    Trials
    Company:
    EMD Serono, Takeda
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. (PubMed, Front Pharmacol)
    The use of TK inhibitors (gefitinib, erlotinib, lapatinib, and afatinib) and monoclonal antibodies (cetuximab, panitumumab, and matuzumab) in the treatment of advanced-stage cancer is very common. MTT assay, gene expression analysis (BAX, BCL-2, and β-catenin), apoptosis analysis, TEM, cell cycle assay, ELISA, and cell migration assays were conducted to perform the cell death analysis of lung cancer and breast cancer, compared to the marketed product. The MTT assay exhibited 80% cell death for 75 µM and 100µM; however, flow cytometry analysis with the IC value demonstrated that the selected compound induced higher apoptosis in MCF-7 (30.8%) than in A549.
    Preclinical • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BAX (BCL2-associated X protein)
    |
    BCL2 expression • BAX expression
    |
    Erbitux (cetuximab) • erlotinib • Gilotrif (afatinib) • gefitinib • Vectibix (panitumumab) • lapatinib • matuzumab (EMD 72000)